James Alan Shriver Nightingale

Title: James Alan Shriver Nightingale: Innovator in Pharmaceutical Compositions

Introduction

James Alan Shriver Nightingale is a notable inventor based in Bend, Oregon. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions that enhance drug delivery. His innovative work focuses on cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors.

Latest Patents

Nightingale holds a patent for "Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase." This patent describes a solid amorphous dispersion that includes a cholesteryl ester transfer protein (CETP) inhibitor, an HMG-CoA reductase inhibitor, and a concentration-enhancing polymer. The unique aspect of this invention is that a major portion of the CETP inhibitor in the dispersion is amorphous, which provides concentration enhancement when administered in an aqueous environment.

Career Highlights

Nightingale is associated with Bend Research, Inc., where he applies his expertise in pharmaceutical sciences. His work has contributed to advancements in drug formulations that improve therapeutic efficacy.

Collaborations

He has collaborated with notable colleagues such as Dwayne Thomas Friesen and Bruno Caspar Hancock, further enhancing the innovative environment at Bend Research, Inc.

Conclusion

James Alan Shriver Nightingale is a distinguished inventor whose work in pharmaceutical compositions has the potential to significantly impact drug delivery systems. His contributions reflect a commitment to advancing healthcare through innovation.